SomaLogic

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.

SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

SomaLogic headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical Device, Health Diagnostics sector. The company focuses on Biotechnology and has secured $260.2B in funding across 272 round(s). With a team of 501-1000 employees, SomaLogic is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - SomaLogic, raised $10.0M. Discover more about their projects, partnerships, and impact on our platform.